| Filed On | Filing |
|---|---|
| 12 Nov 2026 | 8-K: Results of Operations and Financial Condition |
| 10 Nov 2026 |
8-K: Other Events
Azitra, Inc. to Present Research at BIO-Europe® Showing ATR-COSF Reduced Fine Lines and Improved Elasticity in Ex Vivo Human Skin Models |
| 29 Oct 2026 |
8-K: Other Events
Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial to Include Patients with Rashes due to KRAS and MEK Inhibitors |
| 26 Oct 2026 |
8-K: Other Events
ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin. |
| 22 Oct 2026 |
8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year
Azitra, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify: |
| 01 Oct 2026 |
8-K: Other Events
BRANFORD, Conn. – October 1, 2026 — Azitra, Inc. (“Azitra” or the “Company”) (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the comp... |
| 28 Sep 2026 |
8-K: Entry into a Material Definitive Agreement
Azitra, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with A.G.P./Alliance Global Partners (the “Sales Agent”), as follows: |
| 08 Sep 2026 |
8-K: Regulation FD Disclosure
BRANFORD, Conn. – September 8, 2026 — Azitra, Inc. (“Azitra” or the “Company”) (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic... |
| 21 Aug 2026 |
8-K: Other Events
BRANFORD, Conn. – August 21, 2026 — Azitra, Inc. (“Azitra” or the “Company”) (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic p... |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition
BRANFORD, Conn. – August 12, 2026 — Azitra, Inc. (“Azitra” or the “Company”) (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic p... |
| 15 Jul 2026 |
8-K: Other Events
Azitra, Inc. Announces Breakthrough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity |
| 17 Jun 2026 |
8-K: Other Events
Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond |
| 16 Jun 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
Azitra, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify: |
| 04 Jun 2026 |
8-K: Other Events
BRANFORD, Conn. – June 4, 2026 - Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced its 2026 Annual Meeting, originally sch... |
| 27 May 2026 |
8-K: Other Events
BRANFORD, Conn. – May 27, 2026 - Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it intends to convene its upcoming... |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition
BRANFORD, Conn. – May 13, 2026 — Azitra, Inc. (“Azitra” or the “Company”) (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial re... |
| 23 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
This Securities Purchase Agreement (this “Agreement”) is dated as of March 18, 2026, between Azitra, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successor... |
| 13 Mar 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Other Events
BRANFORD, Conn. - March 13, 2026 /PRNewswire/ - Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced it received a notice fro... |
| 05 Mar 2026 |
8-K: Other Events
BRANFORD, Conn., March 5, 2026 /PRNewswire/ — Azitra, Inc. (NYSE American: AZTR) (“Azitra” or the “Company”), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announce... |
| 27 Feb 2026 |
8-K: Results of Operations and Financial Condition
BRANFORD, Conn. – February 27, 2026 — Azitra, Inc. (“Azitra”) (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for th... |
Loading...